Alaunos Therapeutics, Inc. SEC filings TCRT
Alaunos Therapeutics, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Apr 1, 2010. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| CORRESP | Letter to the SEC | Oct 1, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2025 | — |
| CORRESP | Letter to the SEC | Sep 8, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 2, 2025 | — |
| EFFECT | Filing | Sep 7, 2022 | — |
| CORRESP | Letter to the SEC | Sep 2, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 19, 2022 | — |
| NT 10-Q | Filing | Aug 9, 2021 | Jun 30, 2021 |
| SEC STAFF LETTER | Filing | Mar 11, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 10, 2021 | — |
| DFAN14A | Filing | Dec 17, 2020 | — |
| DFAN14A | Filing | Dec 14, 2020 | — |
| DFAN14A | Filing | Dec 8, 2020 | — |
| DFAN14A | Filing | Dec 3, 2020 | — |
| DFAN14A | Filing | Dec 2, 2020 | — |
| DFAN14A | Filing | Nov 30, 2020 | — |
| DFAN14A | Filing | Nov 27, 2020 | — |
| DFAN14A | Filing | Nov 24, 2020 | — |
| DFAN14A | Filing | Nov 23, 2020 | — |
| DFAN14A | Filing | Nov 19, 2020 | — |
| DFAN14A | Filing | Nov 18, 2020 | — |
| DFAN14A | Filing | Nov 16, 2020 | — |
| DFAN14A | Filing | Nov 13, 2020 | — |
| DFAN14A | Filing | Nov 12, 2020 | — |
| DFAN14A | Filing | Nov 5, 2020 | — |
| DFRN14A | Filing | Nov 4, 2020 | — |
| DFAN14A | Filing | Nov 2, 2020 | — |
| DEFC14A | Filing | Nov 2, 2020 | — |
| DEFC14A | Filing | Oct 30, 2020 | — |
| PRRN14A | Filing | Oct 29, 2020 | — |
| PRRN14A | Filing | Oct 28, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 28, 2020 | — |
| PRER14A | Preliminary revised proxy statement | Oct 27, 2020 | — |
| CORRESP | Letter to the SEC | Oct 27, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2020 | — |
| PRRN14A | Filing | Oct 26, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 22, 2020 | — |
| PREC14A | Preliminary proxy statement | Oct 21, 2020 | — |
| PREC14A | Filing | Oct 16, 2020 | — |
| D | Filing | Sep 17, 2019 | — |
| D | Filing | Aug 9, 2019 | — |
| EFFECT | Filing | Feb 21, 2019 | — |
| CORRESP | Letter to the SEC | Feb 19, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2019 | — |
| D | Filing | Nov 19, 2018 | — |
| CT ORDER | Filing | Nov 19, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2017 | — |
| CORRESP | Letter to the SEC | Dec 12, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 29, 2016 | — |
| D | Filing | Jul 7, 2016 | — |
| CT ORDER | Filing | Jan 22, 2016 | — |
| CT ORDER | Filing | Dec 17, 2015 | — |
| CT ORDER | Filing | Jun 12, 2015 | — |
| CT ORDER | Filing | Mar 20, 2015 | — |
| D | Filing | Jan 28, 2015 | — |
| UPLOAD | Letter from the SEC | Jul 18, 2013 | — |
| CORRESP | Letter to the SEC | Jun 28, 2013 | — |
| UPLOAD | Letter from the SEC | Jun 14, 2013 | — |
| D | Filing | Nov 21, 2012 | — |
| EFFECT | Filing | Nov 16, 2011 | — |
| EFFECT | Filing | Jul 18, 2011 | — |
| CORRESP | Letter to the SEC | Jul 14, 2011 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2011 | — |
| CORRESP | Letter to the SEC | Jun 8, 2011 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2011 | — |
| CT ORDER | Filing | Mar 15, 2011 | — |
| D | Filing | Jan 14, 2011 | — |
| UPLOAD | Letter from the SEC | Dec 21, 2010 | — |
| CORRESP | Letter to the SEC | Dec 10, 2010 | — |
| UPLOAD | Letter from the SEC | Dec 3, 2010 | — |
| CORRESP | Letter to the SEC | Oct 15, 2010 | — |
| CORRESP | Letter to the SEC | Oct 1, 2010 | — |
| UPLOAD | Letter from the SEC | Sep 20, 2010 | — |
| EFFECT | Filing | May 13, 2010 | — |
| CORRESP | Letter to the SEC | May 11, 2010 | — |
| UPLOAD | Letter from the SEC | May 7, 2010 | — |
| CORRESP | Letter to the SEC | Apr 30, 2010 | — |
Showing 77 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TCRT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Lauderdale, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1107421
- Former names
- ZIOPHARM ONCOLOGY INC (until Jan 4, 2022); EASYWEB INC (until Sep 19, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.